MX2009008914A - Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. - Google Patents
Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.Info
- Publication number
- MX2009008914A MX2009008914A MX2009008914A MX2009008914A MX2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A
- Authority
- MX
- Mexico
- Prior art keywords
- metalloproteins
- antibodies
- pharmaceutical compositions
- compositions containing
- inhibiting activity
- Prior art date
Links
- 102000010750 Metalloproteins Human genes 0.000 title 1
- 108010063312 Metalloproteins Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/06—Zinc compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90285407P | 2007-02-23 | 2007-02-23 | |
| PCT/IL2008/000230 WO2008102359A1 (en) | 2007-02-23 | 2008-02-21 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009008914A true MX2009008914A (es) | 2009-08-28 |
Family
ID=39534848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009008914A MX2009008914A (es) | 2007-02-23 | 2008-02-21 | Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8324355B2 (OSRAM) |
| EP (1) | EP2155691B1 (OSRAM) |
| JP (2) | JP5513130B2 (OSRAM) |
| KR (1) | KR20090113908A (OSRAM) |
| CN (1) | CN101702906B (OSRAM) |
| BR (1) | BRPI0807256A2 (OSRAM) |
| CA (1) | CA2678304A1 (OSRAM) |
| IL (2) | IL224120A (OSRAM) |
| MX (1) | MX2009008914A (OSRAM) |
| RU (1) | RU2503682C2 (OSRAM) |
| WO (1) | WO2008102359A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2155691B1 (en) | 2007-02-23 | 2016-01-13 | Yeda Research and Development Co. Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| EP2231186A4 (en) | 2007-12-17 | 2012-08-08 | Dyax Corp | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS |
| CA2717803A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| EP2403964B1 (en) * | 2009-03-02 | 2021-09-08 | Massachusetts Institute of Technology | Methods and products for in vivo enzyme profiling |
| CA2787311C (en) | 2010-01-27 | 2017-08-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
| PE20131376A1 (es) | 2010-08-27 | 2013-11-25 | Gilead Biologics Inc | Anticuerpos para metaloproteinasa-9 de matriz |
| CN103370337B (zh) * | 2010-10-28 | 2015-12-09 | 耶达研究及发展有限公司 | 用于产生针对金属酶的抗体的方法 |
| US10314909B2 (en) | 2011-10-21 | 2019-06-11 | Dyax Corp. | Combination therapy comprising an MMP-14 binding protein |
| EP2819697A4 (en) | 2012-02-29 | 2016-03-09 | Gilead Biologics Inc | ANTIBODIES AGAINST METALLOPROTEINASE 9 OF MATRIX |
| CN118010994A (zh) | 2013-06-07 | 2024-05-10 | 麻省理工学院 | 基于亲和力检测配体编码的合成性生物标记物 |
| RU2729546C2 (ru) | 2014-04-03 | 2020-08-07 | Цсл Беринг Аг | Распыление иммуноглобулина |
| US11153875B2 (en) | 2014-05-19 | 2021-10-19 | Qualcomm Incorporated | Apparatus and method for inter-band pairing of carriers for time division duplex transmit- and receive-switching and its application to multiplexing of different transmission time intervals |
| US11357022B2 (en) | 2014-05-19 | 2022-06-07 | Qualcomm Incorporated | Apparatus and method for interference mitigation utilizing thin control |
| EP2985296A1 (en) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| WO2017176017A1 (en) * | 2016-04-04 | 2017-10-12 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting and receiving feedback in wireless communication system |
| US11352436B2 (en) * | 2017-02-10 | 2022-06-07 | Washington University | Antibodies to TIP1 and methods of use thereof |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| US11926655B2 (en) | 2017-07-18 | 2024-03-12 | Daiichi Sankyo Company, Limited | Active MMP9-binding peptide |
| US12173349B2 (en) | 2018-09-25 | 2024-12-24 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| IL264768A (en) * | 2019-02-10 | 2020-08-31 | Sagi Irit | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use |
| US11332546B2 (en) | 2019-05-21 | 2022-05-17 | The Regents Of The University Of California | Protease inhibitory antibodies and methods of use thereof |
| WO2025075789A1 (en) * | 2023-10-03 | 2025-04-10 | Merck Sharp & Dohme Llc | Immunoassay for detecting tau phosphorylated at serine 413 |
| WO2025076280A1 (en) | 2023-10-05 | 2025-04-10 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| EP0634998B1 (en) | 1992-04-07 | 1997-03-19 | British Biotech Pharmaceuticals Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
| GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| AU2394795A (en) | 1994-04-28 | 1995-11-29 | Du Pont Merck Pharmaceutical Company, The | Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents |
| WO1995029689A1 (en) | 1994-04-28 | 1995-11-09 | Merck & Co., Inc. | N-carboxyalkyl derivatives as antidegenerative active agents |
| GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
| EP0757984B1 (en) | 1995-08-08 | 2002-10-30 | Ono Pharmaceutical Co., Ltd. | Hydroxamic acid derivatives useful for inhibiting gelatinase |
| IL116126A0 (en) * | 1995-11-24 | 1996-01-31 | Yeda Res & Dev | Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| PT871439E (pt) | 1996-01-02 | 2004-08-31 | Aventis Pharma Inc | Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo) |
| WO1997049679A1 (en) | 1996-06-27 | 1997-12-31 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| IL140746A0 (en) | 1998-07-30 | 2002-02-10 | Warner Lambert Co | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| IL132105A0 (en) * | 1998-12-24 | 2001-03-19 | Yeda Res & Dev | Caspase-8 interacting proteins |
| DK2330132T3 (da) * | 2003-04-04 | 2013-11-04 | Yeda Res & Dev | Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet |
| EP2155691B1 (en) | 2007-02-23 | 2016-01-13 | Yeda Research and Development Co. Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| CA2787311C (en) | 2010-01-27 | 2017-08-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
-
2008
- 2008-02-21 EP EP08710230.7A patent/EP2155691B1/en not_active Not-in-force
- 2008-02-21 CA CA002678304A patent/CA2678304A1/en not_active Abandoned
- 2008-02-21 RU RU2009132006/04A patent/RU2503682C2/ru not_active IP Right Cessation
- 2008-02-21 JP JP2009550773A patent/JP5513130B2/ja not_active Expired - Fee Related
- 2008-02-21 KR KR1020097019866A patent/KR20090113908A/ko not_active Ceased
- 2008-02-21 CN CN200880012673.1A patent/CN101702906B/zh not_active Expired - Fee Related
- 2008-02-21 BR BRPI0807256-6A2A patent/BRPI0807256A2/pt not_active IP Right Cessation
- 2008-02-21 WO PCT/IL2008/000230 patent/WO2008102359A1/en not_active Ceased
- 2008-02-21 MX MX2009008914A patent/MX2009008914A/es not_active Application Discontinuation
- 2008-02-21 US US12/449,728 patent/US8324355B2/en active Active
-
2012
- 2012-08-28 US US13/596,090 patent/US8486653B2/en active Active
-
2013
- 2013-01-06 IL IL224120A patent/IL224120A/en active IP Right Grant
- 2013-01-06 IL IL224121A patent/IL224121A/en active IP Right Grant
- 2013-04-29 US US13/872,265 patent/US9416195B2/en not_active Expired - Fee Related
- 2013-07-19 JP JP2013150040A patent/JP5792231B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-23 US US15/161,375 patent/US9902783B2/en active Active
-
2018
- 2018-01-09 US US15/865,479 patent/US20180134808A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8324355B2 (en) | 2012-12-04 |
| CN101702906B (zh) | 2014-02-12 |
| US20130224225A1 (en) | 2013-08-29 |
| US8486653B2 (en) | 2013-07-16 |
| EP2155691B1 (en) | 2016-01-13 |
| JP5792231B2 (ja) | 2015-10-07 |
| US20100233188A1 (en) | 2010-09-16 |
| RU2503682C2 (ru) | 2014-01-10 |
| US20160257765A1 (en) | 2016-09-08 |
| US20180134808A1 (en) | 2018-05-17 |
| RU2009132006A (ru) | 2011-02-27 |
| JP5513130B2 (ja) | 2014-06-04 |
| BRPI0807256A2 (pt) | 2014-07-22 |
| JP2013241435A (ja) | 2013-12-05 |
| WO2008102359A1 (en) | 2008-08-28 |
| IL224121A (en) | 2016-05-31 |
| US9902783B2 (en) | 2018-02-27 |
| AU2008218525A1 (en) | 2008-08-28 |
| CN101702906A (zh) | 2010-05-05 |
| US20130030158A1 (en) | 2013-01-31 |
| WO2008102359A9 (en) | 2009-05-22 |
| US9416195B2 (en) | 2016-08-16 |
| IL224120A (en) | 2016-05-31 |
| JP2010519289A (ja) | 2010-06-03 |
| KR20090113908A (ko) | 2009-11-02 |
| EP2155691A1 (en) | 2010-02-24 |
| CA2678304A1 (en) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009008914A (es) | Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. | |
| BRPI0513990A (pt) | composições de silano, processos para suas preparações e composições de borracha contendo as mesmas | |
| NO20091706L (no) | Inhibitorer av hepatitt C virus | |
| ATE296797T1 (de) | N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese | |
| EA200870358A1 (ru) | 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1 | |
| ATE427932T1 (de) | 11beta-hsd1-inhibitoren | |
| NO20084701L (no) | Ny heterocyklisk forbindelse eller salt eller intermediat derav | |
| EA200700699A1 (ru) | Ингибиторы взаимодействия между mdm2 и p53 | |
| EA201171328A1 (ru) | Производное замещенного изохинолина | |
| NO20091704L (no) | Inhibitorer av hepatitt C virus | |
| JO2644B1 (en) | Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use | |
| NO20091707L (no) | Inhibitorer av hepatitt C virus | |
| MY149180A (en) | Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof | |
| BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
| ATE341591T1 (de) | Perylenpigmentzusammensetzungen | |
| EA200800822A1 (ru) | Конъюгаты гидроксиалкилкрахмала и действующего вещества, полученные химическим лигированием через тиазолидин | |
| EP1775289A4 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
| PL1951747T3 (pl) | Sposób syntezy i związki pośrednie do syntezy kaspofunginy | |
| WO2006060424A3 (en) | Inducible nitric oxide synthase dimerization inhibitors | |
| EP1961734A4 (en) | AMINE CONNECTION AND ITS USE FOR MEDICAL PURPOSES | |
| ES2199696A1 (es) | Mezclas de estabilizantes | |
| TW200716089A (en) | BCRP/ABCG2 inhibitor | |
| DE602004003948D1 (de) | Herstellung von 2-18f-2-desoxy-d-glucose durch festphasensynthese | |
| HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| WO2006103101A3 (en) | MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |